Recommendation of the President – Agamree (vamorol)
On 24 February 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 30/2026 on the reimbursement of the medicinal product Agamree (vamorol) under the drug program “Treatment of patients with Duchenne muscular dystrophy (DMD) (ICD-10: G71.0)”